)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Candel Therapeutics (CADL) investor relations material
Candel Therapeutics Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Presentation summary10 Dec, 2025
Clinical pipeline and product highlights
CAN-2409 is an off-the-shelf viral immunotherapy with positive phase 3 results in prostate cancer, and phase 2a data in pancreatic and NSCLC, showing improved survival and strong safety profile.
CAN-3110 is an oncolytic HSV-1 virus with proof of concept in recurrent high-grade glioma, demonstrating encouraging survival and immune activation, with Fast Track and Orphan Drug designations.
Both products are protected by long-term IP and data exclusivity, with low-cost manufacturing and precommercialization activities underway for CAN-2409.
Cash position of $87M as of September 2025, with a term loan facility of up to $130M, providing runway into Q1 2027.
Experienced leadership and a renowned scientific advisory board support ongoing development and commercialization.
CAN-2409 in prostate cancer: clinical and commercial outlook
Phase 3 trial in intermediate/high-risk localized prostate cancer (n=745) met primary endpoint, showing a 30% risk reduction in disease recurrence (HR=0.70, p=0.0155) and 38% reduction in prostate cancer-specific recurrence (HR=0.62, p=0.0046).
Significant improvements in PSA nadir rates and pathological complete response at 2 years (80.4% vs 63.6% for placebo, p=0.0015).
Well-tolerated with lower rates of serious adverse events and treatment discontinuation compared to placebo.
Addressable US market estimated at $10–16B, with strong payor support for reimbursement and pricing in line with other prostate cancer therapies.
BLA submission expected in Q4 2026, with comprehensive commercial launch planning and stakeholder engagement underway.
CAN-2409 in pancreatic and lung cancer: clinical data
In borderline resectable pancreatic cancer, phase 2a trial showed median OS of 31.4 months for CAN-2409 vs 12.5 months for control, with 71.4% 24-month survival rate and favorable safety.
In NSCLC patients with inadequate response to ICI, phase 2a trial showed mOS of 24.5 months (all), 21.5 months (progressive disease), and 25.4 months (nonsquamous), all exceeding historical controls.
Systemic antitumor activity observed, including abscopal effects and long-term survival in a significant subset of patients.
Safety profile in both indications was favorable, with most adverse events mild to moderate.
CAN-2409 prostate cancer market access strategy
Compare CAN-2409 and CAN-3110 MOA and scope
CAN-3110 expansion beyond brain cancers strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Candel Therapeutics earnings date
Q4 202513 Mar, 2026
Next Candel Therapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer treatment. The company’s approach involves using genetically modified viruses to induce immunogenic cell death in cancer cells, which unmask tumor antigens within an activated microenvironment. This process triggers a systemic and durable immune response against tumors, acting as an in situ vaccination. Candel’s therapies are designed to potentially improve survival rates and maintain the quality of life for patients across various stages of cancer. The company is headquartered in Needham, Massachusetts, and its shares are listed on NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage